Equibles does not estimate personal net worth.
Get an email with a short summary when Arcus Biosciences, Inc. publishes a filing, an earnings call transcript or a press release.
Get RCUS alertsBob Goeltz is recorded as CFO at Arcus Biosciences, Inc. (RCUS). Bob Goeltz has spoken on 6 earnings calls and 4 other investor events across 1 company, most recently for Arcus Biosciences, Inc. on October 20, 2026. Arcus Biosciences, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Arcus Biosciences, Inc. includes Terry Rosen (CEO and Board Member), Robert C. Goeltz II (CFO and Chief Accounting Officer), Robert Goeltz (CFO) and 7 others.
“I can comment on the financial arrangements first. So we haven't disclosed the financial arrangements, but I would just comment, and we said this previously, that if you look at the totality of our collaborations with BMS, with Pfizer, and with Summit, the aggregate of those is very financially attractive to ARCUS.”
“Yeah, I think, you know, Terry described the potential for us to differentiate on the majority of patients that are coming into the second line that have previously seen a TKI.”
“We think that there's a good potential here. And we think it's really, frankly, the potential for the mechanism. It's just we think a lot of the belzutafan data indicates what belzutafan can achieve, not what a great HIF2-alpha inhibitor can achieve.”
“Before I get into the quarter's financials, I want to spend a few minutes on the multibillion dollar market opportunity for CasDataphan. Sales for RCC drugs in just the major markets are expected to grow to roughly $13 billion by 2030.”
“We'll have the 31 patients for the CAS, ZIM. The median follow-up will probably be in the 8- to 10-month range. So we'll have, like, an early look at efficacy there.”
Biotechnology · Healthcare
CFO
